Paul Lin

The University of Texas MD Anderson Cancer Center — United States

Immunology and Microbiology · Life Sciences

26h-index3.3kcitations110works12.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(33), Multiple Myeloma Research and Treatments(29), CAR-T cell therapy research(21), Protein Degradation and Inhibitors(10), Mesenchymal stem cell research(9)

Publications110 total

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.
Blood·2025Open Access
Optimizing essential, complex hematologic care for patients living with disabilities
Blood·2025
CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
Blood Cancer Discovery·2025· 1 citedOpen Access
267 Genome-wide KO Screen (GWS) to uncover genes promoting premature termination codon readthrough
Journal of Cystic Fibrosis·2025
DVRD Induction Followed by Autologous Hematopoietic Stem Cell Transplantation for Older Patients with Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
DKRD vs. DVRD Induction Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency
Cancer Cell·2025· 12 citedOpen Access
Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant
Transplantation and Cellular Therapy·2025
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells
Nature·2025· 24 citedOpen Access
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation
Transplantation and Cellular Therapy·2025
Abstract 3763: Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency
Cancer Research·2025
Abstract 6396: CREM is a regulatory checkpoint of CAR and IL-15 signaling in NK cells
Cancer Research·2025
Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response
British Journal of Haematology·2025· 1 cited
Daratumumab-Based Second Line Therapy Improves Outcomes after VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance
Transplantation and Cellular Therapy·2025
Outcomes of Patients with IgD Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant
Transplantation and Cellular Therapy·2025
Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells
Cell Reports·2025· 6 citedOpen Access
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation
Transplantation and Cellular Therapy·2024· 1 cited
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant
British Journal of Haematology·2024· 1 citedOpen Access
Conditioning with Busulfan + Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis
Blood·2024
Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
Blood·2024
page 1 of 6Next →

Frequent Co-authors

Elizabeth J. Shpall(20), Richard E. Champlin(16), Rafet Başar(14), May Daher(14), Pinaki P. Banerjee(14), Katayoun Rezvani(14), Mayra Shanley(13), Ye Li(12), Nadima Uprety(12), Sunil Acharya(12), Ken Chen(11), Luis Muniz-Feliciano(11), David Marín(10), Hind Rafei(10), Ana Karen Nunez Cortes(10), Enli Liu(9), Mecit Kaplan(8), Muzaffar H. Qazilbash(8), Luciana Melo Garcia(8), Krina K. Patel(8)